Mesoblast/$MESO
1D1W1MYTD1Y5YMAX
Capital at risk
About Mesoblast
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
- Ticker
- $MESO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 108
- Headquarters
- Melbourne, Australia
- Website
- www.mesoblast.com
Mesoblast Metrics
BasicAdvanced
$2B
-
-$0.04
0.81
-
Price and volume
Market cap
$2B
Beta
0.81
52-week high
$21.50
52-week low
$13.05
Average daily volume
198K
Financial strength
Current ratio
2.435
Quick ratio
1.98
Long term debt to equity
0.2
Total debt to equity
0.224
Interest coverage (TTM)
-2.58%
Profitability
EBITDA (TTM)
-44.605
Gross margin (TTM)
80.02%
Net profit margin (TTM)
-47.82%
Operating margin (TTM)
-42.62%
Effective tax rate (TTM)
-1.08%
Revenue per employee (TTM)
$1,110,000
Management effectiveness
Return on assets (TTM)
-4.11%
Return on equity (TTM)
-9.86%
Valuation
Price to revenue (TTM)
162.923
Price to book
4.81
Price to tangible book (TTM)
1,344.81
Price to free cash flow (TTM)
-438.017
Free cash flow yield (TTM)
-0.23%
Free cash flow per share (TTM)
-0.035
Growth
Revenue change (TTM)
599.21%
Earnings per share change (TTM)
-47.51%
3-year revenue growth (CAGR)
152.15%
10-year revenue growth (CAGR)
10.95%
3-year earnings per share growth (CAGR)
-25.01%
10-year earnings per share growth (CAGR)
14.53%
What the Analysts think about Mesoblast
Analyst ratings (Buy, Hold, Sell) for Mesoblast stock.
Analyst projections of the future price of Mesoblast stock.
Bulls say / Bears say
Ryoncil® delivered net revenue of US$36 million in Q4 FY2026 and US$115 million for the full year ended June 30, 2026, demonstrating strong commercial uptake post-launch (SEC)
Mesoblast received FDA IND clearance on April 7, 2026 to directly proceed to a registrational Ryoncil® trial in Duchenne muscular dystrophy, opening access to a U.S. patient population of approximately 15,000 children (SEC)
In late June 2026, Mesoblast secured a BLA filing number and requested a modular review from FDA for rexlemestrocel-L to prevent life-threatening gastrointestinal bleeding in LVAD patients, supported by RMAT and Orphan Drug designations (SEC)
Mesoblast completed patient treatment in its pivotal Phase 3 trial for chronic low back pain, but top-line results are not expected until mid-calendar 2027, extending a critical data readout and investor uncertainty (MarketScreener)
Despite FY2026 revenue growth to US$120.3 million, Mesoblast’s net operating cash spend was US$43.8 million with year-end cash of US$103 million drawn from a US$125 million facility, highlighting ongoing cash burn and reliance on external financing (Reuters via Bitget)
As of June 30, 2026, Mesoblast had accumulated net losses of US$1.07 billion since inception, underscoring a prolonged unprofitable operating history (MarketScreener)
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2026.
Mesoblast Financial Performance
Revenues and expenses
Mesoblast Earnings Performance
Company profitability
Upcoming events
No upcoming events
Mesoblast News
AllArticlesVideos
Funds containing Mesoblast
AllUSDGBPEUR
Fund name | Fund size | $MESO weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.05% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.05% |
SPDR MSCI All Country World IM€SPYI | €7.5B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.